Company PixarBio Corporation

PixarBio Corporation is a specialty pharmaceutical company that is focused on the pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain. The Company’s lead product platform, NeuroRelease, is a novel biodegradable microparticle delivery system for the delivery of non-opiate prescription paid drugs. NeuroRelease offers sustained therapeutic pre-clinical release over time of a non-opiate drug for post-operative, acute, and chronic pain in pre-clinical models involving rodents and pigs. NeuroRelease treats multiple conditions, including pain, Parkinson’s disease, epilepsy, and spinal cord injury. NeuroRelease is biodegradable, and it is non-toxic so it can be re-injected to extend treatment timelines. Its Injectable NeuroScaffold is a platform to advance from acute neuro-protective spinal cord injury treatment to a regeneration treatment for chronic spinal cord injury.

Number of employees: 30